Overview

MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)

Status:
Recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

A phase II, Multi-centre, randomised, double-blind, placebo-controlled, Multi-arm parallel cohort trial. - to investigate the effect of 2.5 mg/kg og ATG on the preservation of stimulated C-peptide at 12 months compared to placebo - to identify the minimally effective dose of ATG that shows an effect on C-peptide when compared to placebo at 12 months

Phase:

Phase 2

Details

Lead Sponsor:

Universitaire Ziekenhuizen Leuven

Treatments:

Antibodies
Immunoglobulins
Immunoglobulins, Intravenous
Thymoglobulin